Ascletis Pharma has reported positive topline Phase III results showing that denifanstat (ASC40), a first-in-class oral FASN inhibitor for moderate-to-severe acne, delivered a favorable long-term ...

HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...

Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.

Sagimet Biosciences (SGMT) stock dips as Chinese partner Ascletis (ASCLF) reports Phase 3 trial data for the U.S. firm's acne drug denifanstat (ASC40). Read more here.

When you buy through links on our articles, Future and its syndication partners may earn a commission. In a clinical trial, scientists are investigating whether a vaccine could treat patients with ...

Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...

Almirall’s Seysara receives China NMPA approval for treatment of moderate-to-severe acne: Barcelona, Spain Saturday, January 31, 2026, 11:00 Hrs [IST] Almirall, S.A, a global ph ...

Regularly touted for its health benefits, the Mediterranean diet has been given another endorsement by German scientists who have found it helps reduce acne. The team found that this diet's focus on ...

The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...

The incidence of acne varies by transgender status, in a multicenter cohort study of transgender individuals starting hormone ...